Companies › Aragon Pharmaceuticals
1 active drug program in 29 registered trials: 15 Phase 2, 12 Phase 3, 2 Phase 1; Oncology; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Apalutamide (ARN-509) Androgen Receptor antagonist | AR | Phase 3 | Prostatic Neoplasms; Prostate Cancer; Prostatic Neoplasms, Castration-Resistant; Androgen Axis Suppression … | Mar 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06758882 | Apalutamide (ARN-509) | Phase 2 | High Risk Prostate Cancer | Oncology | Jan 2026 |
| NCT06067269 | Apalutamide (ARN-509) | Phase 2 | Prostate Adenocarcinoma | Oncology | Dec 2026 |
| NCT05406999 | Apalutamide (ARN-509) | Phase 2 | Neoadjuvant Therapy | Oncology | Dec 2026 |
| NCT03902951 | Apalutamide (ARN-509) | Phase 2 | Metastatic Prostate Adenocarcinoma | Oncology | Jan 2027 |
| NCT03436654 | Apalutamide (ARN-509) | Phase 2 | Prostate Cancer | Oncology | Feb 2027 |
| NCT02531516 | Apalutamide (ARN-509) | Phase 3 | Prostatic Neoplasms | Oncology | Mar 2027 |
| NCT04812366 | Apalutamide (ARN-509) | Phase 2 | Prostate Cancer | Oncology | Jun 2027 |
| NCT02949284 | Apalutamide (ARN-509) | Phase 2 | Stage II Prostate Adenocarcinoma | Oncology | Jun 2027 |
| NCT06274047 | Apalutamide (ARN-509) | Phase 3 | Androgen Axis Suppression | Oncology | Jun 2027 |
| NCT07260435 | Apalutamide (ARN-509) | Phase 3 | Prostate Cancer | Oncology | Nov 2027 |
| NCT01946204 | Apalutamide (ARN-509) | Phase 3 | Prostatic Neoplasms | Oncology | Dec 2027 |
| NCT02257736 | Apalutamide (ARN-509) | Phase 3 | Prostatic Neoplasms | Oncology | Dec 2027 |
| NCT02489318 | Apalutamide (ARN-509) | Phase 3 | Prostate Cancer | Oncology | Dec 2027 |
| NCT02123758 | Apalutamide (ARN-509) | Phase 1 | Prostatic Neoplasms | Oncology | Dec 2027 |
| NCT02592317 | Apalutamide (ARN-509) | Phase 1 | Prostatic Neoplasms, Castration-Resistant | Oncology | Dec 2027 |
| NCT06832774 | Apalutamide (ARN-509) | Phase 2 | Prostate Cancer Metastatic Disease | Oncology | Dec 2027 |
| NCT04267887 | Apalutamide (ARN-509) | Phase 2 | Castration-Sensitive Prostate Carcinoma | Oncology | Jan 2028 |
| NCT03412396 | Apalutamide (ARN-509) | Phase 2 | Prostate Adenocarcinoma | Oncology | Mar 2028 |
| NCT02703623 | Apalutamide (ARN-509) | Phase 2 | Castration Levels of Testosterone | Oncology | Mar 2028 |
| NCT04181203 | Apalutamide (ARN-509) | Phase 3 | Prostate Cancer | Oncology | Sep 2028 |
| NCT03821792 | Apalutamide (ARN-509) | Phase 2 | Metastatic Prostate Carcinoma | Oncology | Oct 2028 |
| NCT04295447 | Apalutamide (ARN-509) | Phase 2 | Prostatic Neoplasms | Oncology | Nov 2028 |
| NCT07751133 | Apalutamide (ARN-509) | Phase 3 | Prostate Cancer | Oncology | Aug 2029 |
| NCT05191680 | Apalutamide (ARN-509) | Phase 2 | Prostate Cancer | Oncology | Oct 2029 |
| NCT03371719 | Apalutamide (ARN-509) | Phase 2 | Recurrent Prostate Carcinoma | Oncology | Mar 2030 |
| NCT07333066 | Apalutamide (ARN-509) | Phase 3 | Metastatic Hormone-sensitive Prostate Cancer | Oncology | Mar 2030 |
| NCT04134260 | Apalutamide (ARN-509) | Phase 3 | Prostate Adenocarcinoma | Oncology | Nov 2031 |
| NCT04423211 | Apalutamide (ARN-509) | Phase 3 | Biochemically Recurrent Prostate Carcinoma | Oncology | Dec 2032 |
| NCT04513717 | Apalutamide (ARN-509) | Phase 3 | Prostate Adenocarcinoma | Oncology | Dec 2033 |
Tolmar Amneal Pharmaceuticals LaNova Medicines Zhejiang Quetzal Therapeutics Beijing Pearl Biotechnology Limited Liability Company
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.